Novavax Inc. ($NVAX) Stock Forecast: Down 10.4% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company specializing in vaccine development, particularly for infectious diseases such as COVID-19. The stock's performance is influenced by its activities in the vaccine industry.

Why is Novavax Inc. going down?

NVAX stock is down 10.4% on Nov 15, 2024 14:46

• NVAX displayed a downward trend in trading today.
• The market's response was adverse following the announcement of Robert F. Kennedy Jr., known for his skepticism towards vaccines, being appointed to lead the HHS, leading to a decline in vaccine-related stocks.
• Although NVAX posted better-than-expected earnings and revenue for Q3, the stock price dropped as company officials revised their sales forecast downwards, citing reduced uptake of the COVID-19 vaccine.
• Despite the recent decline, a notable uptick in options trading favoring NVAX suggests continued positive investor sentiment for the company's long-term outlook.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS

President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.

https://www.zacks.com/stock/news/2370835/vaccine-stocks-fall-after-trump-selects-rfk-jr-to-lead-hhs

Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS

Shares of Moderna, Novavax, Pfizer, BioNTech and GSK closed lower on Thursday.

https://www.cnbc.com/2024/11/14/vaccine-maker-stocks-fall-as-trump-chooses-rfk-jr-to-lead-hhs.html

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.

https://www.zacks.com/stock/news/2369460/novavax-q3-earnings-sales-beat-stock-falls-6-on-24-view-cut

Novavax ( NVAX ) Reports Q3 Loss, Tops Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2368779/novavax-nvax-reports-q3-loss-tops-revenue-estimates

Spotlight on Novavax: Analyzing the Surge in Options Activity - Novavax ( NASDAQ:NVAX )

Deep-pocketed investors have adopted a bullish approach towards Novavax NVAX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

https://www.benzinga.com/insights/options/24/11/41886814/spotlight-on-novavax-analyzing-the-surge-in-options-activity

Trending Today

Memecoin ($MEME) Crypto Forecast: Down 9.8% Today

Decentraland ($MANA) Crypto Forecast: Down 5.2% Today

The Sandbox ($SAND) Crypto Forecast: Down 6.1% Today

Optimism ($OP) Crypto Forecast: Down 5.2% Today

Arbitrum ($ARB) Crypto Forecast: Down 5.8% Today

Bittensor ($TAO) Crypto Forecast: Down 6.8% Today

Litecoin ($LTC) Crypto Forecast: Down 5.5% Today

Zillow Group Inc. ($Z) Stock Forecast: Up 5.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 6.0% Today

NEM ($XEM) Crypto Forecast: Down 5.6% Today

Novavax Inc. Price History

17.09.2024 - NVAX Stock was down 5.0%

• Novavax's stock plummeted after the FDA placed a hold on its COVID-19-flu combination and stand-alone flu vaccines due to a study participant reporting nerve damage. This news caused concerns among investors and led to a sharp decline in the stock price.
• The clinical hold on Novavax's vaccine programs raised doubts about the safety and efficacy of their products, resulting in a loss of investor confidence and a sell-off of NVAX shares.
• Despite the broader market decline, Novavax's stock stood out with a substantial decrease, indicating that the FDA's decision had a more pronounced impact on the company's valuation compared to other market factors.

15.10.2024 - NVAX Stock was down 10.4%

• NVAX displayed a downward trend in trading today.
• The market's response was adverse following the announcement of Robert F. Kennedy Jr., known for his skepticism towards vaccines, being appointed to lead the HHS, leading to a decline in vaccine-related stocks.
• Although NVAX posted better-than-expected earnings and revenue for Q3, the stock price dropped as company officials revised their sales forecast downwards, citing reduced uptake of the COVID-19 vaccine.
• Despite the recent decline, a notable uptick in options trading favoring NVAX suggests continued positive investor sentiment for the company's long-term outlook.

28.09.2024 - NVAX Stock was up 5.6%

• Despite the overall bearish market sentiment, Novavax (NVAX) experienced a strong bullish movement.
• Highlighting a slight decrease in Novavax's stock price could be a short-term fluctuation, possibly overshadowed by positive news or developments within the company.
• Investors might be reacting positively to potential advancements in Novavax's vaccine development or clinical trial results, driving the stock price higher.
• It's essential to monitor further updates from Novavax to understand the sustainability of this bullish trend amidst broader market conditions.

11.10.2024 - NVAX Stock was down 10.5%

• The green signal from the FDA for Novavax's COVID-19-influenza combo vaccine late-stage trial potentially boosted investor confidence.
• Concerns surrounding the upcoming Q3 earnings report, with anticipated negative earnings and uncertainties about exceeding expectations, likely triggered the sell-off of NVAX shares.
• Ongoing discussions with the FDA regarding the removal of the clinical hold on its vaccine programs may have introduced uncertainty into the stock's performance, influencing today's bearish trend.

11.10.2024 - NVAX Stock was down 6.2%

• Concerns may have arisen among investors about Novavax's ability to meet market expectations following the FDA's approval for the company's COVID-19-influenza combo vaccine late-stage trial.
• The bearish movement in NVAX's stock price could be attributed to the anticipation of negative earnings and uncertainties surrounding the company's upcoming report.
• A sell-off of NVAX shares in the market may be a result of investors' cautious approach towards the company's financial performance and its potential impact on stock value.

11.10.2024 - NVAX Stock was down 10.2%

• Despite receiving FDA approval for the late-stage trial of its COVID-19-influenza combination vaccine, Novavax (NVAX) observed a downturn in its stock performance today.
• Increased options trading activity and anticipation surrounding the upcoming third-quarter earnings announcement likely heightened volatility in the stock price.
• Investors might have had elevated hopes for positive updates regarding the FDA's removal of the clinical hold during the earnings call, resulting in disappointment and a negative market response.
• The company's stock faced downward pressure possibly due to the absence of favorable factors for a potential earnings surpass, as per recent analysis.

13.10.2024 - NVAX Stock was down 6.4%

• The company shared strong Q3 earnings and revenue figures, but the stock dropped 6% following a reduction in sales forecast due to lower COVID-19 vaccine demand.
• Despite the positive financial results, the stock was impacted by the revised sales guidance.
• The FDA's approval for Novavax's late-stage trial of a COVID-19-influenza combination vaccine could have a favorable long-term effect on the stock, but the current downward movement might be due to short-term worries regarding sales expectations.

16.09.2024 - NVAX Stock was down 17.1%

• Novavax's combination Covid-flu shot and influenza vaccine trial faced a setback as the FDA placed a hold due to a single report of nerve damage in a patient, leading to concerns and uncertainty among investors.
• The clinical hold on Novavax's IND application for its COVID-19-influenza combination and stand-alone influenza vaccine candidates resulted in a plunge in the stock price, with investors reacting to the setback in the development of these crucial vaccines.
• Despite the broader market decline, Novavax managed to close with a slight positive shift, indicating that investors are closely monitoring the situation and potential updates regarding the FDA's decision on the trial.

18.09.2024 - NVAX Stock was up 6.1%

• NVAX stock experienced a bullish movement despite the FDA placing a hold on its COVID-19-flu combination and stand-alone flu vaccines due to a reported issue in a study participant.
• Investors may be optimistic about Novavax's ability to address regulatory concerns and resolve the challenges with its vaccine programs.
• The market's positive response to these updates may indicate confidence in Novavax's overall pipeline and potential for advancements in the vaccine industry.

30.09.2024 - NVAX Stock was down 6.1%

• NVAX demonstrated bearish movement, performing below the market average.
• The decline in NVAX's stock price could be linked to profit-taking following a recent bullish period.
• Investors may be wary due to uncertainties regarding the efficacy and distribution of Novavax's COVID-19 vaccine candidate.
• Market growth may have prompted a shift of investments from high-risk biotech stocks like NVAX to more secure options.

05.10.2024 - NVAX Stock was up 5.5%

• Despite concerns about potential negative earnings and a slight dip in the stock price, Novavax (NVAX) experienced a strong bullish movement today.
• The market may be reacting positively to potential positive developments in Novavax's vaccine research or other promising company news.
• Investors might be optimistic about Novavax's future prospects, leading to increased buying activity and driving the stock price higher.
• It's essential to keep an eye on upcoming earnings reports and any significant updates from Novavax to gauge the sustainability of this bullish momentum.

12.10.2024 - NVAX Stock was down 5.8%

• The bearish movement in NVAX stock today could be attributed to the company reporting a Q3 loss despite topping revenue estimates, raising concerns about its profitability and financial health.
• The surge in options activity with a bullish approach from deep-pocketed investors may have initially boosted optimism, but the market sentiment might have shifted due to the reported loss.
• The FDA's green signal for Novavax's COVID-19-influenza combo vaccine late-stage trial could have been a positive catalyst, but investors might be waiting for more concrete updates on the clinical hold removal from the upcoming earnings call.
• The upcoming Q3 earnings report will be crucial for NVAX, as investors are eagerly awaiting management's updates on regulatory discussions and the company's overall performance, which could further influence the stock movement.